Pacritinib
- Generic Name
- Pacritinib
- Brand Names
- Vonjo
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32N4O3
- CAS Number
- 937272-79-2
- Unique Ingredient Identifier
- G22N65IL3O
- Background
Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. While some patients may remain asymptomatic, typical symptoms of MF arise from abnormali...
- Indication
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10/L.
...
- Associated Conditions
- High-Risk Secondary Myelofibrosis, High risk Primary Myelofibrosis (PMF), Intermediate risk Primary Myelofibrosis (PMF), Intermediate risk Secondary Myelofibrosis
- Associated Therapies
- -
Will The Upcoming Trial Updates On Elritercept Revive KROS's Momentum?
Keros Therapeutics Inc. (KROS) to update on phase II trials of Elritercept for ineffective hematopoiesis in MDS and MF this quarter. Elritercept shows potential to increase RBC and platelet production, with durable transfusion independence in lower-risk MDS and broader clinical benefits in MF. Additional data expected in Q4 2024. Keros also has Cibotercept in phase II for pulmonary arterial hypertension and KER-065 in phase I for obesity and neuromuscular disorders.
Fennec Pharmaceuticals Strengthens Executive Leadership
Fennec Pharmaceuticals appoints Pierre S. Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer to strengthen its executive team and accelerate the commercialization of PEDMARK, the first therapy to reduce ototoxicity risk from cisplatin treatment in pediatric patients.
Swedish Orphan Biovitrum Has Built a Narrow Moat Around Hematology and Immunology Products
Since 2016, Sobi has expanded from a European specialty pharmaceutical firm to include US markets and new therapeutic areas in immunology and hematology through successful drug launches and acquisitions, warranting a narrow moat rating.
Reducing Our Uncertainty Rating to Medium
Morningstar lowers Swedish Orphan Biovitrum's Uncertainty Rating to Medium from High due to diversified revenue via acquisitions in hematology and immunology. Hemophilia drug revenue concentration has declined from 60% in 2018 to 40% in 2023, expected to drop to mid-30s. New products like Altuviiio, SEL-212, and Vonjo will drive future growth. Fair value estimate remains SEK 343 with a narrow moat rating; shares appear undervalued.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath